How did Fractyl document its development decision?

In its October 22, 2026 disclosure, Fractyl said it would stop internal development of its Rejuva gene therapy program and explore other options.

What to check after reading

Record the company's development decision in the project timeline. Record findings from human studies with their own sources.

Source

Fractyl Form 8‑K in the SEC archive ↗

Calendar dates show when a case was added or scheduled. For event dates, check the original source.